TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00843713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raltegravir
Description: For patients assigned to the raltegravir group, subjects will receive raltegravir 400mg to be taken by mouth twice daily for 24 weeks in addition to taking their current HIV medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For the patient assigned to the placebo group, subjects will take a matching placebo pill 400mg to be taken by mouth twice daily for 24 weeks in addition to taking their current HIV medication
Study: NCT01404091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2940094
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2940094
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2940094
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2940094
Description: Administered orally
Study: NCT01890772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telaprevir
Study: NCT01915173

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Interview
Study: NCT04294602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise therapy intended in reducing muscle spasm, improving coordination of the mastication muscles and alter the jaw closure pattern.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise therapy intended in reducing muscle spasm, improving coordination of the mastication muscles and alter the jaw closure pattern.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise therapy intended in reducing muscle spasm, improving coordination of the mastication muscles and alter the jaw closure pattern.
Study: NCT01890772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telaprevir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Study: NCT02881996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV tylenol
Description: IV tylenol given scheduled in addition to standard PCA
Study: NCT04294602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: LLLT (max output power: 1200mW, wavelength: 808 nm, dosage: 10j/ cm2 Electronica Pagani Laser Tower Light, Italy) 2.5-4j/TrP dosage was applied to MTrP or sensitive points.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manuel Pressure Release
Description: MPR technique is a noninvasive method based on pressure on the trigger point in accordance with the patient's tolerance and technique applies supine position relax as much as possible, manuel pressure applied trigger point in neck and mactication muscles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: Some suggestions were made to TMD people who should pay attention to in daily life. These suggestions were given in writing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: Some suggestions were made to TMD people who should pay attention to in daily life. These suggestions were given in writing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: Some suggestions were made to TMD people who should pay attention to in daily life. These suggestions were given in writing.
Study: NCT02881996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No IV tylenol
Description: No additional IV Tylenol given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: both groups receive as part of our standard postop pain protocol after all operations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: both groups receive as part of our standard postop pain protocol after all operations
Study: NCT00787189

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Hearing Laser
Description: Two 6-minute low level laser light applications to the head/neck/ears region, each one week apart.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser
Description: inactive low level laser light therapy with no therapeutic output
Study: NCT02502045

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Morning Simulated Sunlight
Description: Timed morning simulated sunlight (Philips Wake Up Light, Model HF3520) peaking at 300 lux delivered over a 40 minute ramp between 5-9 a.m. for 14 consecutive days

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-therapeutic Red Light
Description: Non-therapeutic red light control at 5 lux will be used as the control condition
Study: NCT03079895

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thrive
Description: Thrive is an online self-help tool designed to assess for depressive symptoms and give therapeutic suggestions based on Cognitive Behavioral Therapy principals.
Study: NCT01517555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: liraglutide
Description: Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
Study: NCT03808298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Moxifloxacin Treatment D
Description: Day 2: A single oral dose of a matching placebo capsule for moxifloxacin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Moxifloxacin Treatment D
Description: Day 2: A single oral dose of a matching placebo capsule for moxifloxacin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Treatment D
Description: Day 15: A single oral dose of 400 mg moxifloxacin capsule.
Study: NCT02530424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab (8 mg/kg loading dose IV, then 6 mg/kg IV) will be given on day 1 q. 3 weeks for a total of 6 administrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab (840 mg as an i.v. infusion) will be given on day 1 q. 3 weeks for a total of 6 administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib will be given at the dose of 125 mg po q.d. x 21 every 4 weeks (i.e. 1 week rest period for a total of 5 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant will be administered according to local prescription guidelines and will be given intra-muscle at the dose of 500 mg every 4 weeks (repeat for 5 times) with an additional 500 mg dose given two weeks after the initial dose
Study: NCT01427088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CR Technology, TAMAS for repetitive TMS
Description: repetitive TMS, lef DLPFC, 20Hz, 100% of MEP, 2weeks
Study: NCT03808298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Treatment D
Description: Day 15: A single oral dose of 400 mg moxifloxacin capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Treatment D
Description: Day 15: A single oral dose of 400 mg moxifloxacin capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Treatment D
Description: Day 15: A single oral dose of 400 mg moxifloxacin capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Treatment D
Description: Day 15: A single oral dose of 400 mg moxifloxacin capsule.
Study: NCT01517555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: One single dose of 1 g. Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paracetamol
Description: One single dose of 1 g. Tablet
Study: NCT01425125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan in euvolemic hyponatremia
Description: This arm will test the effectiveness of tolvaptan in treating the hyponatremia of patients with euvolemic hyponatremia.
Study: NCT03456232

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-flux hemodialysis
Description: High-flux hemodialysis using diffusion, ultrafiltration and convection principle to remove harmful substances in the blood and excessive water.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hemodiafiltration
Description: Hemodiafiltration is a combination of hemodialysis and hemofiltration with two modes of treatment advantages, both by diffusion and convection principle to remove harmful substances in the blood.
Study: NCT03755882

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE® DEFINE™ Vivid Style
Description: TEST Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE® DEFINE™ Vivid Style
Description: TEST Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LACELLE™ Sparkling Brown
Description: CONTROL Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LACELLE™ Sparkling Brown
Description: CONTROL Lens
Study: NCT01942174

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Prevenar 13
Description: Vaccination at the beginning of the study (day 0)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar 13
Description: Vaccination at the beginning of the study (day 0)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pneumo23 / Pneumovax
Description: Vaccination 2 months later the beginning of the study NB : Vaccine Pneumo23 has been replaced by equivalent vaccine Pneumovax in September 2017 because of the stop of commercialization of Pneumo23 in France by the pharmaceutical company

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumo23 / Pneumovax
Description: Vaccination 2 months later the beginning of the study NB : Vaccine Pneumo23 has been replaced by equivalent vaccine Pneumovax in September 2017 because of the stop of commercialization of Pneumo23 in France by the pharmaceutical company

Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate - Immediate
Description: concerning immediate group, methotrexate is Initiated in the same time that the antipneumococcal vaccination by prevenar 13

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate - Delay
Description: For period group, methotrexate is Initiated \& month after the antipneumococcal vaccination by prevenar 13
Study: NCT03808298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Treatment D
Description: Day 15: A single oral dose of 400 mg moxifloxacin capsule.
Study: NCT04220944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab (200mg) was administered intravenously over 30-60 min every 3 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave Ablation
Description: The ablation area should covered at least two thirds the size of the nodules.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Patient was treated with epirubicin lipiodol emulsion(Epirubicin 40mg, Lipiodol 10ml).Embolic materials such as gelfoam or microsphere was aslo administered until complete stasis in segmental or subsegmental arterial branches.
Study: NCT03221933

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Somatropin Injection low dose group
Description: 0.23mg/kg /wk，inject for seven divided doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Somatropin Injection low dose group
Description: 0.23mg/kg /wk，inject for seven divided doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Somatropin Injection high dose group
Description: 0.46mg/kg /wk，inject for seven divided dose
Study: NCT00387634

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TBE vaccine for adults
Description: Serology blood draw.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TBE vaccine for adults
Description: Serology blood draw.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TBE vaccine for adults
Description: Serology blood draw.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TBE vaccine for adults
Description: Serology blood draw.
Study: NCT03781141

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wound closure
Description: Comparison of two wound closures
Study: NCT03221933

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Somatropin Injection high dose group
Description: 0.46mg/kg /wk，inject for seven divided dose
Study: NCT02288572

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus plantarum PCS 26
Description: Taking dietary supplement on a daily basis which corresponds to 1.000.000.000 CFU of Lactobacillus plantarum PCS 26 per day for 3 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taking dietary supplement on a daily basis for 3 months.
Study: NCT03747575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSTT1041A
Description: Participants will receive subcutaneous (SC) MSTT1041A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive SC placebo
Study: NCT02036892

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling with smartphone
Description: Lifestyle counseling with health promoting smartphone software
Study: NCT03781141

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound closure
Description: Comparison of two wound closures
Study: NCT02036892

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counseling
Description: Lifestyle counseling
Study: NCT02279888

Intervention type: DEVICE
Intervention: CardioMEMS HF System
Description: Pulmonary artery pressure sensor
Study: NCT01585285

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LIMA to SVG Bridge Technique
Description: This surgical design use a composite-sequential venous graft to distribute left internal mammary artery (LIMA) inflow directly to the left anterior descending (LAD), but also to the other branches of the anterolateral territory thereby promoting a higher flow through the LIMA pedicle. It is constructed using a short saphenous vein graft (SVG) bridge interposed between the LAD and one (or more) other anterolateral targets, with the LIMA grafted on the hood of the SVG just above the LAD anastomosis.
Study: NCT00412243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: 40 mg/m\^2 Daily for 3 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Beginning dose 200 mg/m\^2 every 12 hours for 3 days
Study: NCT01944540

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optimized ESD with snaring

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ESD
Study: NCT03223116

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency delivery
Description: Radiofrequency to the gastroesophageal junction
Study: NCT00763919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation module
Description: The psychoeducation module will use psychological and medication education to address opposition to prophylaxis, denial of illness severity or therapeutic effectiveness, negative attitudes toward drugs in general, lack of information about mood stabilizers, and stigma or embarrassment over medications or in relation to the use of complementary or alternative treatments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Substance abuse module
Description: The substance abuse module will address problematic substance abuse, particularly as it relates to medication adherence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improved communication/rapport with provider module
Description: The provider communication and rapport module will improve health care provider communication to address fear of side effects, concern regarding change in appearance, or side effect-related distress.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication routines management module
Description: The medication routines management module will develop strategies and behaviors that help create medication adherence routines for those who have difficulties with medication routines or experience outside opposition to medications.
Study: NCT02659176

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transperineal repair with PIS
Description: Repair of anterior rectocele via transperineal approach followed by limited internal sphincterotomy at 6 o'clock.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transperineal repair without PIS
Description: Repair of anterior rectocele via transperineal approach without performing limited internal sphincterotomy
Study: NCT03671499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognitive Theory based text messages
Description: Participants receive daily text messages and bi-weekly newsletters with information about reducing sitting behavior and increasing physical activity.
Study: NCT02574910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: This is a dose escalation study. Up to 3 successive cohorts of 8 subjects each will receive 7 days of 1, 2 or 4 mg/kg/d of abiraterone acetate, until 7/8 subjects have met the desired endpoint.
Study: NCT01585285

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional CABG
Description: Conventional coronary artery bypass grafting (CABG) strategy with left internal mammary artery (LIMA) graft to the left anterior descending (LAD) and separate sequential aorto-coronary saphenous vein grafts (SVG) to the others anterolateral targets
Study: NCT04553328

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Us guided nerve blocks
Description: The ILIH nerves were identified and located in the fascia compartment between the internal oblique and the transverse abdominis or external oblique muscles, a 20 G needle was advanced between the aponeurosis of the internal oblique and transverses abdominis muscles then 30 ml bupivacaine 0.25% was injected with intermittent aspiration,then 10 ml bupivacaine 0.25% was injected around the nerves.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Us guided nerve blocks
Description: The ILIH nerves were identified and located in the fascia compartment between the internal oblique and the transverse abdominis or external oblique muscles, a 20 G needle was advanced between the aponeurosis of the internal oblique and transverses abdominis muscles then 30 ml bupivacaine 0.25% was injected with intermittent aspiration,then 10 ml bupivacaine 0.25% was injected around the nerves.
Study: NCT00870012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lepicol probiotic & prebiotic formula
Description: NAFLD patients treated with Lepicol probiotic and prebiotic formula for 24 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simple lifestyle advice
Description: NAFLD patients treated with lifestyle advice.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Simple lifestyle advice
Description: NAFLD patients treated with lifestyle advice.
Study: NCT03499834

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Killer Cells (IKC)
Description: Autologous cells of the immune system. Intravenous Injection (I.V.) frequency: One injection per week, twenty-four injections on-treatment
Study: NCT01402713

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1107
Description: GC1107-T5.0: low dose, GC1107-T7.5: high dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1107
Description: GC1107-T5.0: low dose, GC1107-T7.5: high dose
Study: NCT03413618

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
Study: NCT01402713

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TD_PUR INJ / SK Td vaccine
Description: step 1(phase 2)-TD_PUR INJ step 2(phase 3)-SK Td vaccine
Study: NCT02982421

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group art therapy
Description: Participants will engage in an art therapy group tailored at emotion expression related to the experience of breast cancer survivorship.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Participants will receive Psychoeducational material in the form of a lecture and will engage in the coloring of mandalas.
Study: NCT04270968

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extra-corporeal shock wave therapy
Description: Extracorporeal Shock Wave Therapy (ESWT) has been introduced efficiently for more than twenty years as a treatment modality in orthopedic and musculoskeletal disorders. ESWT has mechanical and cellular impacts on tissues regeneration and pain management through cavitation bubbles, acoustic micro streaming, and hyper-vascularity that can directly affect tissue calcifications, and modulate cell activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical none steroidal anti-inflammatory drug
Description: participants received 1% topical diclofenac gel on the tender points 3 times /day for 4 weeks.
Study: NCT04417335

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Description: Bacille Calmette-Guérin is a live attenuated strain of Mycobacterium bovis developed in 1921 to prevent tuberculosis and other mycobacterial related infections.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl
Study: NCT04267835

Intervention type: PROCEDURE
Intervention: MIDCAB
Description: Surgery: MIDCAB

Intervention type: PROCEDURE
Intervention: thoracotomy OPCABG
Description: Surgery: thoracotomy OPCABG